Good morning, it’s Monday, June 2, 2025. We’ve got a loaded line-up of deal news and market-moving events for the days ahead – from a pharma mega-merger to an antitrust nail-biter – all to super-charge your week before the bell.
Deal Radar
Sanofi Goes All-In on Rare Disease with $9.5B Blueprint Deal
Quick Take: Sanofi is paying $129/share (about $9.5 billion) for U.S. biotech Blueprint Medicines – Europe’s biggest pharma acquisition so far this year. The French drugmaker grabs the only approved therapy for systemic mastocytosis, bulking up its immunology portfolio as big pharma’s buyout binge gains steam.
Longer Take: It’s the boldest pharma wager of 2025: Sanofi swooping on Cambridge-based Blueprint and its coveted rare-disease franchise. At $129 per share in cash (a 27% premium to Blueprint’s pre-deal price), Sanofi isn’t just acquiring a pipeline – it’s buying a revenue rocket. Blueprint’s lead drug Ayvakit (for mastocytosis) hit $479 million in sales last year and is growing 60%+ year-on-year. The deal instantly makes Sanofi the leader in this niche, adding the only approved treatment for the disorder alongside several follow-up candidates in trials.
Sanofi’s CEO Paul Hudson calls the buy “a strategic step forward” in transforming into an immunology powerhouse. It’s also part of a shopping spree – Sanofi snapped up two smaller biotechs earlier (Vigil for $470 million, Inhibrx for $2.2 billion) and insists it still has “sizeable capacity” for more deals. Why the urgency? Big pharma is racing to fill pipelines as blockbuster drugs age and R&D gets riskier. Notably, global M&A activity has been in a funk – April saw the fewest deals in 20+ years amid trade-war jitters – but pharma is a bright spot where cash-rich giants are willing to pay for growth. Sanofi’s bet could reignite biotech valuations and spur rivals (think GSK, Novartis) to consider their own get-bigger-or-go-home moves. The big question: will regulators and payers tolerate ever-pricier roll-ups of drug innovators? For now, Sanofi is signaling that if the science is hot, the checkbook is open.
Check out The Closer's free custom GPT trained on thousands of deal memos, academic papers and strategies.
UK Regulator Signals Green Light for SLB’s $8B Oilfield Merger
Quick Take: Britain’s CMA indicated it will likely approve oilfield giant SLB (Schlumberger)’s $8 billion merger with rival ChampionX, after the companies offered sweeping asset sell-offs and tech licenses to ease competition fears A final decision is due by June 11. The surprise turnabout averts a deeper probe and clears a path for SLB to close the deal by early Q3.
Longer Take: The world’s largest oilfield services firm is on the cusp of a major consolidation win – thanks to an unusual concession strategy. SLB’s all-stock takeover of ChampionX (a specialist in drilling chemicals and equipment) raised eyebrows when announced in 2024: combining the No.1 and No.4 players in certain oilfield segments. UK regulators quickly flagged a “substantial lessening of competition” – ChampionX holds ~90% share in some critical drilling sensors and parts, and SLB is a dominant consumer of those parts. The fear? Post-merger, SLB could choke off rivals’ access to key tech, cementing its dominance.
To salvage the deal, SLB and ChampionX went far beyond token fixes. They agreed to divest entire business units (including SLB’s production chemicals arm and ChampionX’s U.S. Synthetic division) and to license crucial technology (like quartz sensors) to third parties on fair terms. This kind of fix-it-first package – essentially carving out pieces of the combined entity before closing – is something the UK’s CMA rarely accepts at Phase 1. Yet the watchdog is provisionally on board, a sign of newfound flexibility in its approach. Insiders note the CMA usually demands “clear-cut” stand-alone sales, but here it’s embracing complex remedies to avoid a protracted fight. If the CMA formally blesses the undertakings by next week, SLB will have dodged a Phase 2 investigation and expects to seal the merger this summer.
The ripple effect: deal advisors are watching if this marks a softer stance by antitrust enforcers in London. After a string of high-profile blockages (Microsoft/Activision infamously) gave the UK a tough-as-nails reputation, a willingness to compromise could encourage more M&A attempts with creative upfront remedies. SLB’s merger – making it an even more formidable one-stop shop from drilling rigs to production chemicals – also reflects how Old Energy firms are bulking up for efficiency as oil stabilizes. The tie-up’s success may spur other industrial deals that seemed unthinkable under strict regulators. For now, SLB has proven that, with enough carve-outs (and some clever lawyering), even a gusher of a merger can flow through the pipes of antitrust scrutiny.
Quick Hits ⚡
- Herc-H&E Closing – U.S. equipment rentals merger wraps up. So what? Creates a ~$5 billion heavyweight as contractors increasingly rent rather than buy.
- Circle IPO – Stablecoin pioneer hits the NYSE (ticker: CRCL) this week. So what? First big crypto listing in ages (targeting a $6.7 billion valuation) tests market appetite.
- Razon’s $896M Gas Grab – Filipino tycoon Enrique Razon to buy 60% of First Gen’s gas-fired power unit. So what? Fuels a cash infusion for First Gen’s renewables expansion plan (4× capacity by 2030).
- Salesforce + Informatica – CRM titan buys data manager Informatica for $8 billion. So what? Arms Salesforce with an AI-ready trove of data tools, bolstering its competitive moat in enterprise software. Read The Closer's Deep Dive from Friday.
- SES–Intelsat Merger – EU decision due by June 10 on the $3.1 billion satellite tie-up (already okayed in the UK). So what? Likely clearance would birth a global satcom giant, pressuring rivals in the space race.
Negotiation Nugget
Use the “Chameleon Effect” – Mirror to win. Subtly mimic your counterpart’s gestures, tone or wording to build rapid rapport. Research shows this tactic dramatically boosts agreement rates: in one experiment, 67% of negotiators reached a deal when a buyer mirrored the seller’s body language, versus just 12.5% without mimicry. The act of mirroring makes the other side feel heard and more trusting, greasing the skids for compromise. Importantly, keep it subtle (no obvious parroting!) – the goal is unconscious bonding. Try nodding, matching their phrasing, or adopting a similar posture next time – you may find the negotiation warming in your favor.
Micro-Chart 📈
Ayvakit Sales Surge
Annual net revenue ($M) - Blueprint's flagship drug
Growth Story: Ayvakit's revenue has grown 24x in just 4 years, with 2024 marking a breakthrough year at nearly $500M. The trajectory suggests Blueprint has found its blockbuster.
Takeaway: Sanofi is buying into Blueprint’s skyrocketing sales – grabbing instant scale in rare disease treatments and revenue growth that would be hard to replicate organically.
Open Thread 🤔
Will Sanofi’s big bet spark a biotech feeding frenzy? Reply and tell us which pipeline (or pharma giant) you’d bet on next.
Or get in touch here.
If you love The Closer, you'll also love Whale Hunting, where the team at Project Brazen explore the hidden world of money and power every week.
